Burosumab
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 372 publications
Research progress on the signaling mechanisms of fibroblast growth factor 23 and its targeted drugs
Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: October 30, 2026
Burosumab-responsive micro tumor-induced osteomalacia caused by a 6-mm phosphaturic mesenchymal tumor of the femoral head: a case report with review of literature on small (≤10 mm) FGF23-producing tumors.
Journal: Endocrine journal
Published: September 27, 2026
From Association to Treatment Threshold: Interpreting Burosumab Dose and HRQoL in Pediatric X-Linked Hypophosphatemia.
Journal: Calcified tissue international
Published: September 18, 2026
Hypophosphataemia in adults: approach to diagnosis and management.
Journal: Internal medicine journal
Published: June 28, 2026
Fibroblast growth factor 23 (FGF23): From synthesis to cleavage.
Journal: Molecular and cellular endocrinology
Published: June 11, 2026
Successful Transition in Rare Metabolic Bone Diseases: One-Year Outcomes of a Multidisciplinary Pediatric-Adult Program.
Journal: Medicina (Kaunas, Lithuania)
Published: May 29, 2026
Hypophosphatemic rickets: diagnosis and treatment.
Journal: Archives of endocrinology and metabolism
Published: May 15, 2026
Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study.
Journal: Calcified tissue international
Published: May 13, 2026
Hyperparathyroidism after 3 years of burosumab in children affected with X-linked hypophosphatemia.
Journal: European journal of endocrinology
Published: April 27, 2026
Last Updated: 11/08/2026